Ipamorelin oral: Frequently asked questions

Prolonged ipamorelin oral taste beyond 5–6 hours suggests either unusually high receptor density, dehydration concentrating peptide in saliva, or accidental re-exposure from contaminated surfaces. Drink 500ml of water over 30 minutes to dilute salivary peptide concentration. Chew sugar-free gum to stimulate saliva production and mechanical receptor turnover. Brush your tongue gently with a soft toothbrush to physically remove surface-bound peptide. If taste persists beyond 8 hours or is accompanied by tingling, numbness, or swelling, contact a healthcare provider—those symptoms suggest allergic reaction or mucosal irritation, not simple taste exposure.

Rinse immediately with cold water for 30 seconds, then follow with a milk rinse or dilute vinegar solution (1 part vinegar to 4 parts water). The goal is to bind free peptide before it attaches to taste receptors. Cold temperature reduces receptor activity, and milk's casein proteins sequester free peptide. Expect some residual bitter taste for 1–2 hours regardless—it won't disappear entirely, but these steps cut duration in half. Avoid hot or warm rinses; heat increases receptor binding affinity and intensifies taste.

Switch to injectable immediately and consider the oral product a learning expense. Oral ipamorelin will not produce measurable GH secretion in any functional assay. Continuing a protocol with a non-viable compound wastes time, funding, and subject recruitment. If your study design requires oral administration for compliance or blinding purposes, reformulate around a compound with demonstrated oral bioavailability (e.g., small-molecule GH secretagogues like MK-677), rather than attempting to salvage an orally administered peptide. Peptides and oral delivery are fundamentally incompatible for molecules above 500 Da molecular weight. Ipamorelin is 711 Da and contains five peptide bonds, all of which are substrates for gastric and intestinal proteases.

Use nitrile gloves during all reconstitution and injection steps—not latex, which is porous and allows peptide to leach through after 10–15 minutes of contact. Change gloves between reconstitution and injection to prevent transferring vial residue to the syringe. Work in a well-ventilated area and avoid talking, yawning, or breathing heavily directly over the vial, which can draw aerosolized peptide particles toward your mouth. Keep a dedicated peptide-handling workspace separate from eating areas, and store a bottle of milk or dilute vinegar nearby as an immediate rinse option if accidental contact occurs.

No. Sublingual absorption bypasses first-pass hepatic metabolism, but it does not bypass salivary amylase or the inevitable swallowing of residual peptide into the stomach. Sublingual mucosa lacks the transporter proteins required for peptide uptake. Compounds absorbed sublingually are typically small lipophilic molecules (nitroglycerin, buprenorphine) with molecular weights below 400 Da. Ipamorelin is 711 Da, hydrophilic, and too large for passive diffusion across buccal epithelium. Sublingual "administration" is sublingual placement followed by gastric degradation after swallowing. Functionally identical to oral tablets. The terminology is marketing differentiation, not pharmacological distinction.

Yes. Subcutaneous injection is the standard administration route for daily peptide protocols in both preclinical and clinical research. A single 5 mg vial of lyophilised ipamorelin reconstituted in 2 mL bacteriostatic water yields 50 doses at 100 mcg per 0.04 mL injection, sufficient for 7 weeks of daily administration in a single subject. Injection site rotation (abdomen, thigh, upper arm) prevents localised irritation, and 29-gauge insulin syringes make subcutaneous administration nearly painless. We've supported research teams running 12-week daily injection protocols with zero compliance issues. The "inconvenience" of injection is vastly overstated compared to the complete lack of efficacy from oral alternatives.